$VNRX News

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

VolitionRx Participates in Launch of DETECSEPS Program in France

VolitionRx Launches DETECSEPS Sepsis Detection Project With ~$7.3M French Government Funding

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

VolitionRx Fully Pays Off $7.5M Convertible Promissory Note, Dated May 20, 2025

Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

Volitionrx Files Prospectus For Offering 10M Common Shares On Behalf Of Selling Shareholders

Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

VolitionRx Reports 112% H1 Revenue Growth, Advances Toward $5M Veterinary Milestone

VolitionRx Announces Publication Of Peer-Reviewed Paper And Editorial Indicating That Its Nu.Q NETs H3.1 Biomarker Is An Independent Predictor Of 28-Day Mortality And Need For Renal Replacement Therapy In Sepsis And Septic Shock Patients

Volition (VNRX) Q2 2026 Earnings Call Transcript

VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript

VolitionRx Limited Q2 2026 Earnings Call Summary

VolitionRX Reports Q2 2026 Results: Full Earnings Call Transcript

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

VolitionRX Q2 EPS $(0.85) Misses $(0.57) Estimate, Sales $398.657K Miss $482.667K Estimate

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients